Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Short Bowel Syndrome 1Pena Shokeir syndrome, type 1 1Hyperphagia 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × soybean oil, phospholipid emulsion × Clear all
NCT02476994 2021-07-21

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Baxter Healthcare Corporation

Phase 4 Terminated
1 enrolled 4 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡